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Stem cells for myocardial repair 
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Summary 
There is a growing interest in the clinical application for stem cell as a 
novel therapy for treatment of acute myocardial infarction and chronic 
myocardial ischaemia. The initial premise is the transplanted exogen-
ous stem cells can engraft and integrate with host myocardium for car-
diac regeneration. However, recent experimental studies suggest that 
multiple mechanisms, including remodelling of extracellular matrix, en-
hancement of neovascularisation and recruitment of endogenous stem 
cells are more likely to contribute to the beneficial effects of stem cell 
therapy that direct trans-differentiation of stem cells into functional 
myocardium. Among different potential cell sources, bone marrow-de-
rived cells and skeletal myoblasts have been tested in pilot clinical 
trials. Phase I/II randomised controlled clinical trials suggest that intra-
coronary or intramyocardial injection of bone marrow-derived cells 
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may be safe and feasible strategies for treatment of acute myocardial 
infarction as well as chronic myocardial ischaemia. In addition, these 
studies show a modest, but significant improvement in left ventricular 
ejection fraction and clinical status of patients after cell transplan-
tation. Nevertheless, most of these studies included a relatively small 
sample size (<200) and short duration of follow-up (<6 months), and 
the clinical efficacy of stem cell therapy need to be confirmed by future 
clinical trials. Furthermore, the optimal timing, cell types and mode of 
delivery need to be addressed, and strategies to improve cell survival 
and engraftment should also be developed to overcome the potential 
hurdles related to cell-based therapy.  
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Introduction 
Coronary artery disease (CAD) remains the major cause of morbid-
ity and mortality worldwide (1). Despite recent advances in reperfu-
sion therapy for acute myocardial infarction (MI) and pharmaco-
therapy for post-MI left ventricular (LV) remodelling, the incidence 
and mortality of post-MI heart failure are increasing (2). There is still 
major unmet need for treatment of post-MI heart failure due to pro-
gressive LV remodelling after initial insult to the myocardium. In pa-
tients with end-stage heart failure, the only available curative therapy 
is heart transplant which is limited by shortage of organs. As a result, 
there is tremendous interest in developing novel therapies for post-
MI LV remodelling and dysfunction. In the last few years, stem cell 
therapies have been investigated as potential treatment for patients 
with acute MI and chronic myocardial ischaemia.  
Mechanisms of action 
The initial premise of cell-based therapy relies on the belief that ex-
ogenous cells or mobilised endogenous cells can transdifferentiate 
into mature cardiomyocytes (CMs) and integrates both electrically 
and mechanically with host CMs to improvement of cardiac function 
(3). Clinical evidence demonstrated that new endogenous or exogen-
ous cells can incorporate into host myocardium via trans-differenti-
ation and/or cell fusion (4). However, emerging data have demon-
strated that cellular mediated paracrine effects are likely the major 
mechanism for the improvement in LV function. Our recent experi-
mental studies (5) and others (6) have shown that the transplanted 
cells can secrete pro-angiogenic cytokines to enhance neovasculari-
sation. The paracrine factors secreted from the transplanted cells exert 
anti-apoptotic effects, alter the restoration of extracellular matrix and 
recruit endogenous stem cells (7). Furthermore, there is very limited 
direct trans-differentiation and long-term survival of transplanted 
cells (8, 9). Indeed, direct injection of cellular extract can provide a 
similar beneficial effects on cardiac function as intact cell therapy (10). 
Different types of cell sources 
Different types of stem or progenitor cells have been investigated 
for cardiac repair including skeletal myoblast, bone marrow (BM)-
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derived cells, placental/cord blood-derived cells, adipose tissue-de-
rived cells, resident cardiac progenitor cells, embryonic stem cells 
(ESC) and recently induced pluripotent stem cells (iPSC). 
Skeletal myoblasts 
Skeletal myoblasts are skeletal muscle precursor cells which can be 
isolated from skeletal muscle biopsies and expanded ex vivo to the 
quantities sufficient for autologous transplantation (11). Experi-
mental studies have demonstrated that transplanted skeletal 
myoblasts engraft and differentiate into myotubules after trans-
plantation, and improve cardiac function in animal model of MI 
(12). However, the major concern of skeletal myoblast is the lack of 
connexin-43 expression after in vitro differentiation and results in 
the failure of electrical integration with the host myocardium to 
cause proarrhythmias (13). Indeed, ventricular tachyarrhythmias 
were observed after skeletal myoblast transplantation in the early 
clinical trials and remains a potential safety issue (11).  
Bone marrow (BM)-derived cells  
BM-derived cells are heterogeneous cellular population consist of 
∼98% differentiated cells (haematopoietic cells, vascular cells, adi-
pocytes, osteoblasts and osteoclasts) and ∼2% stem or progenitor 
cells (haematopoietic stem cells, endothelial progenitor cells [EPC] 
and mesenchymal stem cells [MSC]). BM-derived stem or progeni-
tor cells have been shown to be able to trans-differentiate into vari-
ous cell types of the body including neurons, hepatocytes, skeletal 
muscles and CMs. Similar to skeletal myoblast, BM cells can be 
readily harvested and expanded ex vivo for autologous transplan-
tation without any immune rejection. Experimental studies sug-
gested that transplantation of BM-derived cells into the acute or 
chronic ischaemic myocardium resulted in in vivo myogenesis and 
neo-angiogenesis, and improvement in cardiac function (5, 16). As 
discussed above, the paracrine effects of BM-derived EPC and MSC 
have been postulated as the major mechanism for the improvement 
of cardiac function after transplantation (6, 7). The encouraging re-
sults from pre-clinical studies with different types of BM-derived 
cells (including mononuclear cells, MSC and EPC) resulted in a 
series of pilot clinical trials investigating the potential therapeutic 
use of BM-derived cells in CAD patients. Currently, there is very li-
mited data on the direct comparison of the safety and efficacy be-
tween these different types of BM-derived cell for therapeutic use.  
Other sources of adult stem cells 
EPC cells can also be mobilised from the BM into the peripheral 
circulation with haematopoietic growth factors and then collected 
with an apheresis system for therapeutic use (14, 15). EPCs are 
characterised by their expression of surface markers, such as CD34 
and CD 133. Indeed, these surface antigens are used clinically for 
the isolation of EPC from BM or peripheral blood for therapeutic 
use. Although isolation of the EPC from peripheral blood is less in-
vasive than direct BM cell harvesting, the number of EPC obtained 
from the peripheral blood is lower, and is associated with the cost 
and potential side effects related to the use of growth factors.  
Adipose tissue is another potential source of stem / or progenitor 
cells, including MSC and EPC for cardiac regeneration. Similar to 
BM-derived MCSs, adipose tissue derived MSCs have also been 
shown to differentiate into CM lineage and endothelial lineage, and 
engraft into host myocardium to improve cardiac function (17, 18). 
Placental or cord blood is also a rich source of stem cells, includ-
ing haematopoietic stem cells, MSC and unrestricted somatic stem 
cells (19). They have a high proliferative potential as compared to 
similar cell types derived from adult BM. These cells can be easily 
obtained and cryopreserved after birth for future autologous 
transplantation.  
The presence of resident cardiac stem cells in adult mammalian 
heart has recently been confirmed (20). Resident cardiac stem cells 
can be identified by the expression of c-kit and sca-1 as well as their 
phenotype and ability to differentiate into functional CMs in cul-
ture (21, 22). Clinically, resident cardiac stem cells can be obtained 
from surgical and endomyocardial biopsy, and expanded ex vivo 
for autologous transplantation. In experimental models of MI, 
transplantation or mobilisation of resident cardiac stem cells can 
engraft and acquire cardiac and vascular phenotypes in infarcted 
myocardium to improve cardiac perfusion and function (22). 
Embryonic stem cells (ESC) 
As compared with adult stem cells, ESC can be cultured indefinitely 
(self-renew) in an undifferentiated state without karyotypic alter-
ation. Furthermore, functional CMs with cardiac-specific structural 
and functional properties can be consistently differentiated from 
ESCs with various methods (23). Therefore, ESCs have been con-
sidered as potential unlimited ex vivo cell source for cardiac repair. 
Experimental studies have demonstrated that transplantation of un-
differentiated ESCs or their cardiac derivatives into infarcted myoc-
ardium can consistently improved LV function post-MI (24). Never-
theless, the current efficiency of in vitro cardiac differentiation from 
ESC remains low (typically less than 1%), and a heterogeneous popu-
lation of CMs (pacemakers, atrial, and ventricular cells) with imma-
ture phenotypes are obtained. Together with the potential risk of im-
mune rejection and tumour formation, these issues limited the clini-
cal application of ESC for cardiac regeneration (25).  
Induced pluripotent stem cells (iPSC) 
Recent breakthrough in the generation of human iPSC has at-
tached much attention due to it potential implication on tissue re-
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generation (26). These iPSCs generated from the reprogramming 
process using a combination of transcription factors (Oct3/4, 
Sox2, Klf4 and c-Myc), exhibits essential features of ESCs including 
morphology, surface markers, gene expression profiles and te-
lomerase activity. Experimentally, functional CMs could be differ-
entiated from iPSCs and showed typical features resembling of 
those from ESC-derived CMs (27). One of the potential advan-
tages of iPSCs over ESC is patient-specific stem cells can be ob-
tained for autologous transplantation to avoid the ethical and im-
munological issues related to ESC. However, iPSCs still share some 
of the issues associated with ESC, including the low yield as well as 
the immature and heterogenous phenotypes with cardiac differ-
entiation. Furthermore, the use of viral vectors to create iPSCs may 
lead to uncontrolled cellular proliferation, oncogenesis or abnor-
mal development (28). 
Mode of cell delivery 
Optimal stem cell therapy depends on successful delivery, engraft-
ment and survival of the transplanted cell. The homing and en-
graftment of stem or progenitor cells after administration relies on 
the method of cell delivery, the characteristics of transplanted cells, 
and the host environment (29). In addition to direct cell delivery, 
mobilisation of endogenous stem cell can be achieved by adminis-
tration of cytokines or growth factors. Table 1 summarises the 
potential application as well as advantage and disadvantage of dif-
ferent methods of cell delivery.  
In general, stem cells can be delivered by intravenous or intracor-
onary routes after coronary revascularisation in the setting of acute 
MI. The intravenous infusion is easy available, but have a low efficacy 
for cellular engraftment (<1%) due to the cell trapping in the other 
organs. Selective intracoronary cell injection using the over-the wire 
infusion balloon catheter allows direct delivery of cell to the in-
farcted region. However, both intravenous and intracoronary routes 
are not applicable for patients with an occluded artery and not suit-
able for delivery of stem cells of larger size or limited migration abil-
ity, such as skeletal myoblasts due to risk of microembolisation.  
For patients with chronic myocardial ischaemia not amenable 
to coronary revascularisation, direct intramyocardial injection via 
either surgical epicardial or transcatheter endocardial approaches 
due to low level of expression of homing signal for stem cells. Epi-
cardial injection allows direct visualisation of the targeted regions 
but is only applicable to patients require coronary artery bypass 
grafting. On the other hand, catheter-based endocardial injection 
can be performed as stand-alone procedure, but requires the use of 
special designed injection catheter with or without the use of three 
dimensional electromechanical mapping systems to guide the in-
jection into the targeted regions. These techniques allow direct cell 
delivery into the targeted regions even in patients with occluded 
artery and with the use of certain larger cell types. 
In patients with post-MI heart failure due to large area of in-
farcted and non-viable myocardium, direct injection of stem cells 
Table 1: Advantages and disadvantage of potential clinical strategies for stem cell delivery. 
Strategies Potential clinical 
applications 
Clinical  
experience 
Advantage Disadvantage 
Intravenous  Acute MI +/- ● Easy available and avoid the risk of any  
invasive procedure 
● Low efficacy of cell delivery 
● No applicable to patients with an occluded 
artery 
● Risk of systemic administration unclear  
Intracoronary Acute MI 
Chronic MI 
+++ 
+ 
● Possible wide use in catheterisation  
laboratory 
● Limited risk of systemic administration 
● Clinical trials ongoing  
● Efficacy of cell delivery to the myocardium 
uncertain 
● No applicable to patients with a occluded  
artery 
● No applicable for stem cell with large cells 
Catheter-based  
direct intramyocardial 
injection 
Chronic myocardial  
ischaemia 
Acute MI 
+++ 
+ 
● Avoid the risk of open heart surgery 
● Higher efficacy of cell delivery  
● Short-term safety proven 
● Clinical trials ongoing  
● Need for specialised catheters and imaging 
technology to guide the procedure 
Open heart direct  
epicardial injection 
Chronic myocardial  
ischaemia 
Chronic MI 
++ 
++ 
● Applicable to patients who need open  
heart surgery 
● Allow direct visualisation of the site of  
injection 
● Risk of mortality and morbidity of open  
heart surgery 
Direct epicardial patch Chronic MI - ● Applicable to  
patients who need open heart surgery 
● Avoid uneven distribution of cell in the 
myocardium 
● Allow direct delivery of a large amount of 
cell 
● Need tissue engineering to  
create cellular patch 
● Risk of mortality and morbidity of open  
heart surgery
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into myocardium scar will result in low graft survival and differ-
entiation due to the lack of blood supply as well as paracrine sup-
ports from adjacent host CMs. Therefore, the use of bioengineer-
ing approaches, such as cardiac patches and injectable delivery ma-
trices are needed to improve cell retention, survival and differenti-
ation (30). 
Clinical trials 
Acute myocardial infarction (MI) 
In patients with acute MI, several major randomised controlled 
clinical trials have been reported with the use of intracoronary ad-
ministration of autologous BM cells in patients who had under-
gone successful percutaneous coronary intervention of infarcted 
related artery. As shown in Table 2, these studies yielded mixed 
results on the effect of intracoronary administration of BM cells 
(31–39). The conflicting results of these randomised controlled 
trials may be due to the small patients sample size (<200), their dif-
ferences in the study population, the dosage, preparation and types 
of cells, timing of cell transfer, and the methodology of functional 
assessment. Nevertheless, no major adverse effect was observed in 
all these clinical trials. Several meta-analyses have also been re-
ported on the safety and efficacy of intracoronary BM cell therapy 
during acute MI (40–43). Consistently, all these analysis demon-
strated a modest (∼3–4%) but significant improvement in LV ejec-
tion fraction and a small reduction in infarct scar size and LV di-
mension after intracoronary stem cell therapy as compared with 
controls. This improvement in LV ejection fraction was similar to 
those (∼2.5%) observed in the REPAIR-AMI (Remodelling in 
Acute Myocardial Infarction) trial which is the largest randomised, 
controlled clinical study reported (36). Indeed, these magnitude of 
benefits on LV function observed in stem cell therapy are compat-
ible to those other established therapies for acute MI, such as rep-
erfusion therapies, angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers and beta-blockers (44). The clinical ef-
ficacy of intracoronary BM cells therapy as well as the optimal tim-
ing and dosage of cell administration will be addressed in several 
larger ongoing trials, such as SWISS-AMI and BOOST-2 trials. 
Chronic myocardial ischaemia/ infarction 
In contrast to acute MI, there are only a few small randomised con-
trolled clinical trials on stem cell therapy for treatment of refrac-
Table 2: Randomised controlled trials in acute myocardial infarction. 
 No. of patients Cell types  
& numbers 
(x106) 
Primary 
endpoint 
LVEF (%) Infarct  
size 
Side  
effects 
BOOST 
(31, 32) 
30 vs. 30 controls 2460 BMC with  
gelatine-polysucci-
nate density  
gradient (9.5 CD34+) 
LVEF (MRI), 
safety 
6 months: +6.7% vs. 
+0.7% (↑ 6%) 
18 months:+5.9% vs. 
+3.1% (NS) 
NS Nil 
Jannsens et al. 
(33) 
33 vs. 34 controls 304 BMC with  
Ficoll (2.8 CD34+) 
LVEF (MRI) +3.4% vs. +2.2% (NS) ↓ Nil 
ASTAMI 
(34) 
50 vs. 50 controls  68 BMC with  
Lymphoprep Ficoll 
(0.7 CD34+) 
LVEF, infarct 
size (MRI/ 
SPECT/Echo) 
+1.2% vs. +4.3% (NS) NS Nil 
MAGIC CELL-3-DES 
(35) 
25 vs. 25 controls 1500 G-CSF mobiliz-
ed PBC (7x106 
CD34+) 
LVEF (MRI) +5.5% vs. 0% (↑ 5.5%) ↓ Nil 
REPAIR-AMI  
(36) 
95 vs. 92 controls 236 BMC with Ficoll 
(3.6 CD34+) 
LVEF (LV angi-
ography) 
5.5% vs. +3.0% (↑ 2.5%) NS Nil 
Meluzin et al.  
(37) 
44 (high & low) vs.  
22 controls 
High: 100 BMC 
Low:10 BMC 
LVEF (SPECT) High: +5%; Low: +3%; 
Control:+ 2%  
(↑ 2.0%) 
NS Nil 
REGENT 
(38) 
117 (selected &  
unselected) vs. 20  
controls 
Unselected: 178 
BMC 
Selected: 1.9 
CD34/CXCR4+  
LVEF (MRI) Unselected: +3% 
Selected: +3%  
Control: 0% (NS) 
NA Nil 
FINCELL 
(39) 
40 vs. 40 controls 402 BMC LVEF (ECHO) +7.1% vs. +1.2%  NA Nil 
BMC, bone marrow cells; G-CSF, granulocyte colony stimulating factor; PBC, peripheral blood cells; LVEF, left ventricular ejection fraction; MRI, magnetic  
resonance imaging; NA, not available; NS, non-significant. 
Time to  
therapy 
(days) 
4.8 
1 
6 
4 
4.4 
7 
7 
2–6 
Follow-up 
duration 
(months) 
18 
4 
6 
6 
12 
3 
6 
12 
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tory angina due to chronic myocardial ischaemia or heart failure 
after MI.  
For treatment of refractory angina, clinical trials are mainly fo-
cused on the use of intramyocardial injections of BM cells as 
guided by catheter-based three-dimensional electromechancial 
mapping (45) into chronic ischaemic myocardium which are not 
amenable to conventional coronary revascularisation (Table 3). 
Losordo et al. (46) demonstrated intramyocardial injection of gra-
nulocyte colony-stimulating factor mobilising CD34+ cells im-
proved angina frequency and exercise capacity without any change 
in SPECT perfusion. In contrast, our recent studies (PROTECT-
CAD) (47) and van Ramshorst et al. (48) have shown that intra-
myocardial injection of BM mononuclear cells was associated with 
significant improvement in exercise capacity and clinical status 
(47, 48). As determined by cardiac magnetic resonance imaging, 
patients received BM cell therapy also showed a modest but signifi-
cant improvement in LVEF (3–5%) (47, 48). Although no overall 
improvement in SPECT perfusion was observed in the study by 
Losordo et al. (46) and PROTECT-CAD trial (47), van Ramshorst 
et al. (48) demonstrated a significant improvement in SPECT per-
fusion after BM cell injection. The reasons for the conflicting re-
sults on SPECT remain unclear, but may be related to the differ-
ences in the dosage of cell, study sample size and method of SPECT 
analysis. More importantly, no significant adverse event, including 
cardiac arrhythmias was observed after direct intramyocardial in-
jection of BM cells (46–48). Nevertheless, patients with significant 
Table 3: Randomised controlled trials in chronic myocardial ischaemia. 
Table 4: Randomised controlled trials in congestive heart failure.
 No. of patients Cell types  
& numbers (x106) 
Follow-up  
duration 
(mths) 
Primary  
endpoints 
Secondary endpoints Side  
effects 
Losordo et al.  
(46) 
18 vs. 6 controls 0.05–0.5 per kg G-CSF 
mobilised PBC  
6 Anginal frequency: 
–12.6 vs. –4.5  
(↓8.1, NS) 
Safety: NS 
SPECT perfusion score: –1.5 vs. –2.2 (NS) 
Exercise time: +0.5 vs. +0.3 mins (NS) 
Nil 
PROTECT-CAD  
(47)  
19 vs. 9 controls 42 BMC with Ficoll 
(1.38 CD34+) 
6 Exercise time:  
↑ 53% 
LVEF (MRI): +3.7% vs. –0.4% (↑ 5.4%) 
SPECT perfusion score: –0.5 vs. +2.4 
(↓2.7, NS) 
Nil 
Van Ramshorst et al. 
(48) 
25 vs. 25 controls  98 BMC with Ficoll  6 SPECT perfusion 
score: –3.4 vs. –1.1 
(↓2.44) 
LVEF (MRI): +3% vs. –1% (↑ 3%) 
Exercise capacity: +9W vs. +2W (↑ 7W) 
Nil 
Abbreviations as in Table 1. 
 No. of patients Cell types & 
numbers (x106) 
Follow-up 
duration 
(months) 
Primary  
endpoint 
LVEF (%) LV dimension 
TOPCARE-CHD  
(49) 
24 (PBC), 24 (BMC) 
vs. 23 (controls) 
Intracoronary  
injection: 
22 PBC or 205 BMC 
with Ficoll 
3 LVEF (LV angiogram) PBC: –0.4%; BMC: 
+2.9%; Control: 
–1.2% 
LV EDV- 
PBC: –3%; BMC: 
0%; Control:  
–3% (NS) 
LV ESV- 
PBC: –2%; BMC: 
+2%; Control: 
–1% (NS) 
MAGIC  
(50) 
63 (high and low 
dose) vs. 34 controls 
Epicardial  
injection: 
400 skeletal myo -
blast (low dose);  
800 skeletal myo -
blast (high dose) 
6 LVEF and changes in 
number of  
akinetic segments 
(Echo) 
High dose: +5.2% 
Low dose: +3.4% 
Control: + 4.4%  
(NS) 
LV EDV (ml/m)- 
High:-12.6 
Low:-3.9 
Control:+5.9  
(↓ 12.8) 
LV EDV (ml/m)- 
High:-8.3 
Low:-6.5 
Control:-2.1  
(↓ 8.1) 
Abbreviations as in Table 1; LV, left ventricular; ESV, end-systolic volume; EDV, end-diastolic volume. 
Side  
effects 
Nil 
Non-significant 
higher number  
of arrhythmic 
events in myo-
blast group  
11 Siu et al. Stem cells for myocardial repair
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LV dysfunction were excluded in these trials, therefore, the effects 
of intramyocardial BM cell transplantation in patients with is-
chaemic LV dysfunction need to address in future clinical trials.  
Table 4 summarises two randomised controlled clinical trials 
on the use autologous BM or skeletal myoblast in patients with 
congestive heart failure after MI. In TOPCARE-CHD study, pa-
tients with chronic MI (>3 months) were randomised to receive 
intracoronary transplantation of BM cells or circulating progeni-
tor cells from peripheral blood (49). As compared with controls, 
patients received intracoronary BM cell transplantation but not 
circulating progenitor cells showed a modest but significant im-
provement in LVEF (2.9%) at three months, but no difference in 
LV dimension was observed. The use skeletal myoblast has been in-
vestigated in patients with ischaemic cardiomyopathy. The Myob-
last Autologous Grafting in Ischaemic Cardiomyopathy (MAGIC) 
trial compared the safety and efficacy of low-dose (400 × 106) or 
high-dose (800 × 106) autologous skeletal myoblasts versus place-
bo in patients with ischaemic cardiomyopathy who underwent 
coronary artery bypass grafting (50). Due to the safety concern of 
proarrhythmia, all patients were treated with implantable cardio-
verter-de?brillators before transplantation. Although, there were 
no significant differences in regional or global LV function, and ar-
rhythmia events between patients treated with skeletal myoblast 
versus controls, patients treated with higher dose of cells had a sig-
nificant decrease in LV end-diastolic and end-systolic volume, sug-
gesting the possibility of reverse LV remodelling after stem cell 
therapy (50). 
Future perspectives 
As discussed above, experimental data and pilot human clinical 
trials suggest that cell-based therapy is a safe and feasible option in 
patients with CAD. Despite much heterogeneity in different clini-
cal trials, including cell types, dosage, study design, mode of de-
livery and methodology, there is a modest beneficial effect on the 
LVEF with the use of intracoronary or intramyocardial BM injec-
tion in patients with acute MI or chronic myocardial ischaemia, 
which beyond the magnitude of conventional therapy with a rea-
sonable safety margin. In addition to define the optimal cell type, 
dosage and modes of delivery, further refinement of the thera-
peutic efficacy of cell-based therapy are needed. 
First, the use of autologous BM- or MSC-derived cells is con-
founded by the depletion and/or functional impairment of those 
stem cells associated with aging, diabetes and severe CAD (51). 
Furthermore, the cell preparation and selection procedure can also 
the clinical efficacy of stem cell (52). The use of allogenic cell prod-
ucts with limited immunogenicity, such as MSC derived from dif-
ferent tissues or standardised non-cellular products such as con-
ditional medium or cell extract from different cell source (53) may 
overcome these problems. Furthermore, in vivo modification such 
as hypoxic preconditioning or over-expression of angiogenic 
growth factors before cellular transplantation may also enhance 
the efficacy of stem cell therapy (54, 55).  
Second, transplantation of stem cells that can differentiate into 
functional CMs and integrate with host CMs is required for post-
MI heart failure due to massive loss of CMs. Among different cell 
types, resident cardiac stem cell, ESC and iPSCs are potential can-
didates due to their better potential for proliferation and differ-
entiation into functional CMs. Nevertheless, these cell types also 
have their own limitation as discussed above. Most importantly, 
generation of terminally differentiated and homogeneous func-
tional CMs from these different types of stem cells are essential to 
avoid the issues of teratoma formation and proarrhythmias.  
Third, in vitro cell imaging also confirmed the rate of sustained 
cell engraftment and integration after transplantation remains low 
(56). Therefore, strategies to enhance cell survival after transplan-
tation is equally important to optimal the therapeutic benefits of 
stem cells therapy. The low rate of cell engraftment is attributed by 
the loss of transplanted cells during the cell delivery procedure and 
the mechanical contraction. Furthermore, multiple mechanisms 
including ischaemia, inflammatory reaction, apoptosis and loss of 
cell-cell interactions are likely contribute to the poor survival of 
transplanted cells. The potential solutions to improve cell engraft-
ment and survival included engineering of transplanted cells to en-
hance cell homing and in vitro survival (54, 55, 57), and the use of 
cardiac patches and injectable delivery matrices (30).  
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